Skip to main navigation Skip to search Skip to main content

ROS-Responsive Blended Nanoparticles: Cascade-Amplifying Synergistic Effects of Sonochemotherapy with On-demand Boosted Drug Release During SDT Process

  • Pengying Wu
  • , Wei Dong
  • , Xuyan Guo
  • , Xiaoyang Qiao
  • , Shifang Guo
  • , Lei Zhang
  • , Mingxi Wan
  • , Yujin Zong
  • Xi'an Jiaotong University

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Abstract

Sonodynamic therapy (SDT) not only has greater tissue-penetrating depth compared to photo-stimulated therapies, but also can also trigger rapid drug release to achieve synergistic sonochemotherapy. Here, reactive oxygen species (ROS)-responsive IR780/PTL- nanoparticles (NPs) are designed by self-assembly, which contain ROS-cleavable thioketal linkers (TL) to promote paclitaxel (PTX) release during SDT. Under ultrasound (US) stimulation, IR780/PTL-NPs produce high amounts of ROS, which not only induces apoptosis in human glioma (U87) cells but also boosts PTX released by decomposing the ROS-sensitive TL. In the U87 tumor-bearing mouse model, the IR780/PTL-NPs releases the drug at the target sites in a controlled manner upon US irradiation, which significantly inhibits tumor growth and induces apoptosis in the tumor tissues with no obvious toxicity. Taken together, the IR780/PTL-NPs are a novel platform for sonochemotherapy, and can control the spatio-temporal release of chemotherapeutic drugs during SDT.

Original languageEnglish
Article number1900720
JournalAdvanced Healthcare Materials
Volume8
Issue number18
DOIs
StatePublished - 1 Sep 2019

Keywords

  • ROS-responsive nanoparticles
  • cascade-amplifying synergistic effects
  • on-demand drug release
  • sonochemotherapy

Fingerprint

Dive into the research topics of 'ROS-Responsive Blended Nanoparticles: Cascade-Amplifying Synergistic Effects of Sonochemotherapy with On-demand Boosted Drug Release During SDT Process'. Together they form a unique fingerprint.

Cite this